Based on estrogen receptor (ER), progesterone receptor (PgR) and Her2/neu (HER2) expression, four breast cancer subtypes have been distinguished: luminal A (ER and/or PgR/HER2–, Ki67 <14%), luminal B (ER and/or PgR/HER2–, Ki67 ≥14% or ER and/or PgR/HER2), triple-negative (ER-/PgR-/HER2–), and HER2 (ER-/PgR-/HER2). Our aim was to evaluate the prognosis of these phenotypes in the pre-trastuzumab era in a large cohort of Italian women.
Methods and study design
We studied 2347 breast cancer patients, in stage I-II, registered by the Modena Cancer Registry from 1999 to 2006 in the Modena province, Italy. Overall survival, disease-free survival and second non-mammary tumors were evaluated.
Results
A total of 1868 luminal A (79.6%), 195 luminal B (8.3%), 205 triple-negative (8.7%) and 79 HER2 (3.4%) patients were identified. A better prognosis was observed for luminal A than for luminal B, HER2 and triple-negative subtypes (5-year overall survival, 91% vs 89% vs 87% vs 86%, respectively, P <0.001). Disease-free survival for pT1a and pT1b tumors was worse in HER2 (82%) than in triple-negative (90%), luminal B (95%) and luminal A (97%) (P = 0.013). Finally, luminal B patients had a significantly higher rate of second non-mammary tumors than the other groups.
Conclusions
In the pre-trastuzumab era, luminal A patients showed a better 5-year overall survival than luminal B, HER2 and triple-negative patients, but in terms of disease-free survival, HER2 subtype represented an unfavorable group over time, whereas the triple-negative group had an increased risk of relapse in the first 42 months and then decreased. Among each prognostic factor, ER <10%, Ki67 >14% and HER2 overexpression are considered as risk factors, but only HER2 positivity seems to preserve the role over time.
MenardS., FortisS., CastiglioniF., AgrestiR., BalsariA.: HER2 as a prognostic factor in breast cancer.Oncology, 61 Suppl 2: 67–72, 2001.
2.
WangS.C., HungM.C.: HER2 overexpression and cancer targeting.Semin Oncol, 28 (5 Suppl 16): 115–124, 2001.
3.
HuangE., ChengS.H., DressmanH., PittmanJ., TsouM.H., HorngC.F., BildA., IversenE.S., LiaoM., ChenC.M., WestM., NevinsJ.R., HuangA.: Gene expression predictors of breast cancer outcomes.Lancet, 361(9369): 1590–1596, 2003.
4.
SorlieT., PerouC.M., TibshiraniR., AasT., GeislerS., JohnsenH., HastieT., EisenM.B., van de RijnM., JeffreySS, ThorsenT., QuistH., MateseJ.C., BrownP.O., BotsteinD., Eystein LonningP., Borresen-DaleA.L.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A, 98: 10869–10874, 2001.
5.
SotiriouC., NeoS.Y., McShaneL.M., KornE.L., LongP.M., JazaeriA., MartiatP., FoxS.B., HarrisA.L., LiuE.T.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study.Proc Natl Acad Sci U S A, 100: 10393–10398, 2003.
6.
PerouC.M., SorlieT., EisenM.B., van de RijnM., JeffreyS.S., ReesC.A., PollackJ.R., RossD.T., JohnsenH., AkslenL.A., FlugeO., PergamenschikovA., WilliamsC., ZhuS.X., LonningP.E., Borresen-DaleA.L., BrownP.O., BotsteinD.: Molecular portraits of human breast tumours.Nature, 406: 747–752, 2000.
7.
SotiriouC., PowlesT.J., DowsettM., JazaeriA.A., FeldmanA.L., AssersohnL., GadisettiC., LibuttiS.K., LiuE.T.: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.Breast Cancer Res, 4: R3, 2002.
8.
van't VeerL.J., DaiH., van de VijverM.J., HeY.D., HartA.A., MaoM., PeterseH.L., van der KooyK., MartonM.J., WitteveenA.T., SchreiberG.J., KerkhovenR.M., RobertsC., LinsleyP.S., BernardsR., FriendS.H.: Gene expression profiling predicts clinical outcome of breast cancer.Nature, 415: 530–536, 2002.
9.
van de VijverM.J., HeY.D., van't VeerL.J., DaiH., HartA.A., VoskuilD.W., SchreiberG.J., PeterseJ.L., RobertsC., MartonMJ, ParrishM., AtsmaD., WitteveenA., GlasA., DelahayeL., van der VeldeT., BartelinkH., RodenhuisS., RutgersE.T., FriendS.H., BernardsR.: A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med, 347: 1999–2009, 2002.
10.
SorlieT., TibshiraniR., ParkerJ., HastieT., MarronJ.S., NobelA., DengS., JohnsenH., PesichR., GeislerS., DemeterJ., PerouC.M., LonningP.E., BrownP.O., Borresen-DaleA.L., BotsteinD.: Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A, 100: 8418–8423, 2003.
11.
CheangM.C.U., ChiaS.K., VoducD., GaoD., LeungS., SniderJ., WatsonM., DaviesS., BernardP.S., ParkerJ.S., PerouC.M., EllisM.J., NielsenT.O.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J Natl Cancer Inst, 101: 736–750, 2009.
12.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ and Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol, 22: 1736–1747, 2011.
13.
FoulkesW.D., StefanssonI.M., ChappuisP.O., BeginL.R., GoffinJ.R., WongN., TrudelM., AkslenL.A.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.J Natl Cancer Inst, 95: 1482–1485, 2003.
14.
ModiS., DiGiovannaM.P., LuZ., MoskowitzC., PanageasK.S., Van PoznakC., HudisC.A., NortonL., TanL., SternD.F., CarterD., SeidmanA.D.: Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.Cancer Invest, 23: 483–487, 2005.
15.
Dhesy-ThindB., PritchardK.I., MessersmithH., O'MalleyF., ElavathilL., TrudeauM.: HER2/neu in systemic therapy for women with breast cancer: a systematic review.Breast Cancer Res Treat, 109: 209–229, 2008.
16.
GennariA., SormaniM.P., PronzatoP., PuntoniM., ColozzaM., PfefferU., BruzziP.: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.J Natl Cancer Inst, 100: 14–20, 2008.
17.
ParkS., KooJ.S., KimM.S., ParkH.S., LeeJ.S., LeeJ.S., KimS.I., ParkB.W.: Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.Breast, 21: 50–57, 2012.
18.
VoducK.D., CheangM.C., TyldesleyS., GelmonK., NielsenT.O., KenneckeH.: Breast cancer subtypes and the risk of local and regional relapse.J Clin Oncol, 28: 1684–1691, 2010.
19.
DawoodS., HuR., HomesM.D., CollinsL.C., SchnittS.J., ConnollyJ., ColditzG.A., TamimiR.M.: Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.Breast Cancer Res Treat, 126: 185–192, 2011.
20.
FritzA.: International classification of diseases for oncology (ICD-O).Geneva: World Health Organization; 2000.
21.
KaplanH.G., MalmgrenJ.A.: Impact of triple negative phenotype on breast cancer prognosis.Breast J, 14: 456–463, 2008.
22.
ShoenfeldD.: Partial residuals for the proportional hazard regression model.Biometrika, 69: 239, 1982.
23.
Van HouwelingenJ.C., le CessieS.: Predictive value of statistical models.Stat Med9: 1303–1325, 1990.
24.
DentR., TrudeauM., PritchardK.I., HannaW.M., KahnH.K., SawkaC.A., LickleyL.A., RawlinsonE., SunP., NarodS.A.: Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res, 13: 4429–4434, 2007.
25.
JatoiI., AndersonW.F., JeongJ.H., RedmondC.K.: Breast cancer adjuvant therapy: time to consider its time-dependent effects.J Clin Oncol.29: 2301–2304, 2011.
26.
KaplanH.G., MalmgrenJ.A.: Disease-specific survival in patient-detected breast cancer.Clin Breast Cancer, 7: 133–140, 2006.
Gonzalez-AnguloA.M., LittonJ.K., BroglioK.R., Meric-BernstamF., RakkhitR., CardosoF., PeintingerF., HanrahanE.O., SahinA., GurayM., LarsimontD., FeoliF., StranzlH., BuchholzT.A., ValeroV., TheriaultR., Piccart-GebhartM., RavdinP.M., BerryD.A., HortobagyiG.N.: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.J Clin Oncol, 27: 5700–5706, 2009.
30.
MenardS., CasaliniP., CampiglioM., PupaS., AgrestiR., TagliabueE.: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.Ann Oncol, 12: S15–19, 2001.
31.
KavanaghD.O., ChambersG., O'GradyL., BarryK.M., WaldronR.P., BennaniF., EustaceP.W., TobbiaI.: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?BMC Cancer, 9: 1, 2009.
